GlaxoSmithKline: Making an impact on emerging markets

Authored by Abbas Hussain, Senior Partner, C-Bridge Capital

Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of  emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Building an AI-Ready Workforce

AI is reshaping ways of working faster than most organisations can adapt, putting talent strategy at the top of the Board agenda. Criticaleye's Anna Mitchell asks Board Leaders and CPOs with hands-on experience o...


Richard Williams, Former CHRO at Western Union: How HR Becomes a Board-Level Power Function

Richard Williams, Board Mentor at Criticaleye and former Chief Human Resources Officer (CHRO) at Western Union joins Bridgette Hall, Senior Editor at Criticaleye to explore what it takes to lead HR in a global organi...


Click here to download this insight

VIEWPOINTS | The Sustainability Reset

There’s no doubt that the external narrative around sustainability has shifted over the last 18 months, but behind the scenes companies continue to navigate the challenges and opportunities associated with the ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 201




AlixPartners Drax Group plc Lightsource bp Aldermore Group London Stock Exchange Group E.ON UK NATS Legal & General British Land GlaxoSmithKline plc Hitachi Solutions Stream Mayborn Group Global Payments NatWest Group LACE Partners Rolls-Royce Southern Water